MEP8409A - Fused heterocyclic compound - Google Patents
Fused heterocyclic compoundInfo
- Publication number
- MEP8409A MEP8409A MEP-84/09A MEP8409A MEP8409A ME P8409 A MEP8409 A ME P8409A ME P8409 A MEP8409 A ME P8409A ME P8409 A MEP8409 A ME P8409A
- Authority
- ME
- Montenegro
- Prior art keywords
- optionally
- atom
- optionally substituted
- ring structure
- heterocyclic compound
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- 239000000651 prodrug Chemical class 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/16—Peri-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004165050 | 2004-06-02 | ||
| JP2005058231 | 2005-03-02 | ||
| PCT/JP2005/010451 WO2005118588A1 (ja) | 2004-06-02 | 2005-06-01 | 縮合複素環化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MEP8409A true MEP8409A (en) | 2011-12-20 |
Family
ID=35462874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-84/09A MEP8409A (en) | 2004-06-02 | 2005-06-01 | Fused heterocyclic compound |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US7507740B2 (ja) |
| EP (1) | EP1752457B1 (ja) |
| JP (2) | JP4134227B2 (ja) |
| KR (1) | KR101194622B1 (ja) |
| AU (1) | AU2005250285B2 (ja) |
| BR (1) | BRPI0511768A (ja) |
| CA (1) | CA2569016C (ja) |
| CR (1) | CR8827A (ja) |
| GE (1) | GEP20105024B (ja) |
| IL (1) | IL179414A (ja) |
| MA (1) | MA28973B1 (ja) |
| ME (1) | MEP8409A (ja) |
| MX (1) | MXPA06013996A (ja) |
| NO (1) | NO20066015L (ja) |
| NZ (1) | NZ551938A (ja) |
| RU (1) | RU2389731C2 (ja) |
| TW (1) | TWI392679B (ja) |
| WO (1) | WO2005118588A1 (ja) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200740820A (en) * | 2005-07-05 | 2007-11-01 | Takeda Pharmaceuticals Co | Fused heterocyclic derivatives and use thereof |
| US7932257B2 (en) * | 2005-07-22 | 2011-04-26 | Sunesis Pharmaceuticals, Inc. | Substituted pyrazolo[4,3-d]pyrimidines as aurora kinase inhibitors |
| TW200730527A (en) * | 2005-12-02 | 2007-08-16 | Takeda Pharmaceuticals Co | Fused heterocyclic compound |
| WO2008033745A2 (en) * | 2006-09-11 | 2008-03-20 | Curis, Inc. | Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety |
| US7517882B2 (en) * | 2006-09-18 | 2009-04-14 | Polaris Group | Protein kinase inhibitors |
| CA2665692A1 (en) * | 2006-10-06 | 2008-04-17 | Yoshikazu Ohta | Combination drug |
| CN101611041A (zh) * | 2006-12-12 | 2009-12-23 | 武田药品工业株式会社 | 稠合杂环化合物 |
| US7825127B2 (en) * | 2006-12-28 | 2010-11-02 | Takeda Pharmaceutical Company, Limited | Method for treating cancer |
| JP5516397B2 (ja) * | 2007-04-05 | 2014-06-11 | アムジエン・インコーポレーテツド | オーロラキナーゼ調節物質及び使用方法 |
| EP2155689B1 (en) | 2007-05-31 | 2015-07-08 | Boehringer Ingelheim International GmbH | Ccr2 receptor antagonists and uses thereof |
| US20100183604A1 (en) * | 2007-06-19 | 2010-07-22 | Takeda Pharmaceutical Company Limited | Preventive/remedy for cancer |
| US20110003805A1 (en) * | 2008-03-03 | 2011-01-06 | Takeda Pharmaceutical Company Limited | Concomitant drug |
| WO2009113560A1 (ja) | 2008-03-12 | 2009-09-17 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| MX2010010151A (es) * | 2008-03-20 | 2010-10-25 | Amgen Inc | Moduladores de cinasa aurora y metodo de uso. |
| US9126935B2 (en) | 2008-08-14 | 2015-09-08 | Amgen Inc. | Aurora kinase modulators and methods of use |
| TW201016703A (en) * | 2008-09-26 | 2010-05-01 | Takeda Pharmaceutical | Prevention and treatment of cancer with LKB1 non-expression (deletion or mutation) |
| TW201016704A (en) * | 2008-09-26 | 2010-05-01 | Takeda Pharmaceutical | Prevention and treatment of cancer with RAS gene mutation |
| WO2010036910A1 (en) * | 2008-09-26 | 2010-04-01 | Yoshikazu Ohta | Heart protection by administering an amp-activated protein kinase activator |
| EP2379525B1 (en) | 2008-12-19 | 2015-07-29 | Boehringer Ingelheim International GmbH | Cyclic pyrimidin-4-carboxamides as ccr2 receptor antagonists for treatment of inflammation, asthma and copd |
| JP4892649B1 (ja) | 2009-01-30 | 2012-03-07 | 武田薬品工業株式会社 | 縮合環化合物及びその用途 |
| US8614208B2 (en) * | 2009-08-26 | 2013-12-24 | Takeda Pharmaceutical Company Limited | Fused heterocyclic ring derivative and use thereof |
| WO2011040212A1 (en) | 2009-10-01 | 2011-04-07 | Takeda Pharmaceutical Company Limited | Therapeutic agent for brain tumor |
| MX346393B (es) | 2009-12-17 | 2017-03-17 | Centrexion Therapeutics Corp | Nuevos antagonistas del receptor ccr2 y usos de los mismo. |
| US8946218B2 (en) | 2010-05-12 | 2015-02-03 | Boehringer Ingelheim International Gmbh | CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments |
| EP2569298B1 (en) | 2010-05-12 | 2015-11-25 | Boehringer Ingelheim International GmbH | Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments |
| US8841313B2 (en) | 2010-05-17 | 2014-09-23 | Boehringer Ingelheim International Gmbh | CCR2 antagonists and uses thereof |
| WO2011147772A1 (en) | 2010-05-25 | 2011-12-01 | Boehringer Ingelheim International Gmbh | Ccr2 receptor antagonists |
| EP2576538B1 (en) | 2010-06-01 | 2015-10-28 | Boehringer Ingelheim International GmbH | New CCR2 antagonists |
| CA2760174A1 (en) | 2011-12-01 | 2013-06-01 | Pharmascience Inc. | Protein kinase inhibitors and uses thereof |
| BR112013026521A2 (pt) * | 2011-04-21 | 2016-12-27 | Origenis Gmbh | pirazolo[4,3-d]pirimidinas úteis como inibidores de cinase |
| WO2013010839A1 (en) | 2011-07-15 | 2013-01-24 | Boehringer Ingelheim International Gmbh | Novel and selective ccr2 antagonists |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| LT3049417T (lt) | 2013-07-31 | 2019-02-11 | Merck Patent Gmbh | Piridinai, pirimidnai ir pirazinai kaip btk inhibitoriai ir jų panaudojimas |
| WO2015134539A1 (en) | 2014-03-03 | 2015-09-11 | The Regents Of The University Of California | Mcl-1 antagonists |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| CA2946471C (en) | 2014-04-25 | 2018-08-07 | Pfizer Inc. | Fused bicyclic heteroaromatic compounds and their use as dopamine d1 ligands |
| CR20160512A (es) | 2014-05-01 | 2016-12-21 | Novartis Ag | Compuestos y composiciones como agonistas del receptor tipo toll 7 |
| AU2015253225B2 (en) | 2014-05-01 | 2017-04-06 | Novartis Ag | Compounds and compositions as Toll-Like Receptor 7 agonists |
| BR112017028492B1 (pt) | 2015-07-02 | 2023-12-26 | Centrexion Therapeutics Corporation | Citrato de (4-((3r,4r)-3-metoxitetra-hidro-piran-4- ilamino)piperidin-1-il) (5- metil-6-(((2r, 6s)-6-(p-tolil) tetra-hidro-2h-piran-2-il)metilamino)pirimidin-4-il) metanona, seu uso e seu método de preparação, e composição farmacêutica |
| MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
| EP3591845B1 (en) * | 2018-07-05 | 2023-08-09 | Universite De Bretagne Sud | Sorting device and method for elementary check node processing for message-passing decoding of non-binary codes |
| WO2020118183A1 (en) * | 2018-12-06 | 2020-06-11 | Kapoor Tarun M | 2,4-diaminopyrimidine bicycles for treating cancer |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS554116B2 (ja) * | 1971-08-20 | 1980-01-29 | ||
| ATE151423T1 (de) * | 1993-06-21 | 1997-04-15 | Merrell Pharma Inc | Carbocyclische nucleoside mittel nützlich als selektive inhibitoren von proinflammatorischen cytokinen |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| DK0831829T3 (da) * | 1995-06-07 | 2003-12-15 | Pfizer | Heterocykliske, ringkondenserede pyrimidinderivater |
| US6395733B1 (en) | 1995-06-07 | 2002-05-28 | Pfizer Inc | Heterocyclic ring-fused pyrimidine derivatives |
| PL188959B1 (pl) * | 1995-07-06 | 2005-05-31 | Novartis Ag | Pirolopirymidyny i sposoby ich wytwarzania |
| AR004010A1 (es) | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
| PL190489B1 (pl) | 1996-04-12 | 2005-12-30 | Warner Lambert Co | Nieodwracalne inhibitory kinaz tyrozyny, kompozycja farmaceutyczna je zawierająca i ich zastosowanie |
| TR199900048T2 (xx) | 1996-07-13 | 1999-04-21 | Glaxo Group Limited | Protein tirozin kinaz inhibit�rleri olarak bisiklik heteroaromatik bile�ikler |
| CA2262421C (en) * | 1996-08-23 | 2007-10-02 | Novartis Ag | Substituted pyrrolopyrimidines and processes for their preparation |
| JPH10130258A (ja) | 1996-10-10 | 1998-05-19 | Eli Lilly & Co | ベンゾ［ｂ］チオフェン化合物、中間体、製剤、および方法 |
| BR9713552A (pt) * | 1996-11-27 | 2000-01-25 | Pfizer | Derivados de pirimidina bicìclicos condensados |
| DE69830409T2 (de) | 1997-08-05 | 2006-01-26 | Pfizer Products Inc., Groton | 4-aminopyrrole[3,2-d]pyrimidine als neuropeptid rezeptor antagonisten |
| US6187777B1 (en) * | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
| ATE266662T1 (de) * | 1998-07-22 | 2004-05-15 | Daiichi Suntory Pharma Co Ltd | Nf-kappa b inhibitoren, die indanderivate als aktiven bestandteil enthalten |
| CZ27399A3 (cs) * | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
| JP3270834B2 (ja) | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | 抗がん剤として有用なヘテロ芳香族二環式誘導体 |
| UA71945C2 (en) | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
| WO2001018170A2 (en) * | 1999-08-26 | 2001-03-15 | Plant Research International B.V. | Conditional inhibition of vegetative propagation |
| RU2003134646A (ru) | 2001-04-30 | 2005-04-20 | Глэксо Груп Лимитед (GB) | Конденсированные пиримидины в качестве антагонистов кортикотропинвысокобождающего фактора (crf) |
| US7279474B2 (en) | 2001-04-30 | 2007-10-09 | Glaxo Group Limited | Substituted pyrrolo[2,3-d]pyrimidines as antagonists of the corticotropin releasing factor (CRF) |
| GB0119249D0 (en) | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
| US8507445B2 (en) | 2001-09-07 | 2013-08-13 | Board Of Regents, The University Of Texas System | Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer |
| JP2003183283A (ja) * | 2001-12-18 | 2003-07-03 | Takeda Chem Ind Ltd | 縮合インドール化合物、その製造法および用途 |
| DK1348707T3 (da) | 2002-03-28 | 2010-12-13 | Ustav Ex Botan Av Cr V V I Inst Of Ex Botany Academy Of Sciences Of The Czech Republic Pro | Pyrazolo[4,3-d]pyrimidiner, fremgangsmåder til deres fremstilling samt deres terapeutiske anvendelse |
| US7531553B2 (en) * | 2003-03-21 | 2009-05-12 | Amgen Inc. | Heterocyclic compounds and methods of use |
| US7268133B2 (en) * | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
| WO2004106308A1 (en) | 2003-05-27 | 2004-12-09 | Pfizer Products Inc. | Quinazolines and pyrido [3,4-d] pyrimidines as receptor tyrosine kinase inhibitors |
| US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
| JP2006020985A (ja) | 2004-07-05 | 2006-01-26 | Kiyoshi Owada | 微小孔を用いた入浴剤用炭酸ガス拡散装置 |
| CA2573538C (en) * | 2004-07-30 | 2014-11-25 | Methylgene Inc. | Inhibitors of vegf receptor and hgf receptor signaling |
| US7790729B2 (en) * | 2005-05-20 | 2010-09-07 | Methylgene Inc. | Inhibitors of VEGF receptor and HGF receptor signaling |
| TW200730527A (en) * | 2005-12-02 | 2007-08-16 | Takeda Pharmaceuticals Co | Fused heterocyclic compound |
| CA2665692A1 (en) * | 2006-10-06 | 2008-04-17 | Yoshikazu Ohta | Combination drug |
| US20100183604A1 (en) * | 2007-06-19 | 2010-07-22 | Takeda Pharmaceutical Company Limited | Preventive/remedy for cancer |
| WO2009113560A1 (ja) * | 2008-03-12 | 2009-09-17 | 武田薬品工業株式会社 | 縮合複素環化合物 |
-
2005
- 2005-06-01 ME MEP-84/09A patent/MEP8409A/xx unknown
- 2005-06-01 KR KR1020067027872A patent/KR101194622B1/ko not_active Expired - Fee Related
- 2005-06-01 WO PCT/JP2005/010451 patent/WO2005118588A1/ja not_active Ceased
- 2005-06-01 RU RU2006147267/04A patent/RU2389731C2/ru not_active IP Right Cessation
- 2005-06-01 BR BRPI0511768-2A patent/BRPI0511768A/pt not_active IP Right Cessation
- 2005-06-01 CA CA2569016A patent/CA2569016C/en not_active Expired - Fee Related
- 2005-06-01 EP EP05748463.6A patent/EP1752457B1/en not_active Expired - Lifetime
- 2005-06-01 GE GEAP20059789A patent/GEP20105024B/en unknown
- 2005-06-01 JP JP2006514152A patent/JP4134227B2/ja not_active Expired - Fee Related
- 2005-06-01 MX MXPA06013996A patent/MXPA06013996A/es active IP Right Grant
- 2005-06-01 AU AU2005250285A patent/AU2005250285B2/en not_active Ceased
- 2005-06-01 US US10/592,812 patent/US7507740B2/en not_active Expired - Fee Related
- 2005-06-01 NZ NZ551938A patent/NZ551938A/en not_active IP Right Cessation
- 2005-06-02 TW TW094118122A patent/TWI392679B/zh not_active IP Right Cessation
-
2006
- 2006-11-20 IL IL179414A patent/IL179414A/en not_active IP Right Cessation
- 2006-12-15 MA MA29533A patent/MA28973B1/fr unknown
- 2006-12-22 CR CR8827A patent/CR8827A/es unknown
- 2006-12-27 NO NO20066015A patent/NO20066015L/no not_active Application Discontinuation
-
2008
- 2008-03-26 JP JP2008080528A patent/JP4937172B2/ja not_active Expired - Fee Related
- 2008-07-14 US US12/172,775 patent/US20090203717A1/en not_active Abandoned
- 2008-07-14 US US12/172,631 patent/US8178543B2/en not_active Expired - Fee Related
- 2008-07-14 US US12/172,684 patent/US20090018335A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NO20066015L (no) | 2007-02-13 |
| KR20070026695A (ko) | 2007-03-08 |
| US20070244132A1 (en) | 2007-10-18 |
| CA2569016C (en) | 2012-11-27 |
| WO2005118588A1 (ja) | 2005-12-15 |
| US7507740B2 (en) | 2009-03-24 |
| IL179414A0 (en) | 2007-05-15 |
| AU2005250285B2 (en) | 2011-08-18 |
| US20090203717A1 (en) | 2009-08-13 |
| JP4134227B2 (ja) | 2008-08-20 |
| JP4937172B2 (ja) | 2012-05-23 |
| CA2569016A1 (en) | 2005-12-15 |
| TW200611907A (en) | 2006-04-16 |
| IL179414A (en) | 2013-11-28 |
| TWI392679B (zh) | 2013-04-11 |
| MA28973B1 (fr) | 2007-11-01 |
| US20090029973A1 (en) | 2009-01-29 |
| NZ551938A (en) | 2010-07-30 |
| MXPA06013996A (es) | 2007-02-08 |
| US20090018335A1 (en) | 2009-01-15 |
| KR101194622B1 (ko) | 2012-10-29 |
| GEP20105024B (en) | 2010-06-25 |
| AU2005250285A1 (en) | 2005-12-15 |
| RU2006147267A (ru) | 2008-07-20 |
| EP1752457A4 (en) | 2010-05-26 |
| JPWO2005118588A1 (ja) | 2008-04-03 |
| EP1752457B1 (en) | 2014-03-19 |
| CR8827A (es) | 2007-04-20 |
| US8178543B2 (en) | 2012-05-15 |
| JP2008247907A (ja) | 2008-10-16 |
| BRPI0511768A (pt) | 2008-01-08 |
| RU2389731C2 (ru) | 2010-05-20 |
| EP1752457A1 (en) | 2007-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MEP8409A (en) | Fused heterocyclic compound | |
| EA200800873A1 (ru) | Конденсированные гетероциклические соединения, полезные в качестве модуляторов киназы | |
| WO2007016392A3 (en) | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors | |
| MY153045A (en) | Oxopyrazine derivative and herbicide | |
| CY1114932T1 (el) | Αντιπαρασιτικοι παραγοντες | |
| CY1111922T1 (el) | 1-ετεροκυκλυλσουλφονυλ, 2-αμινομεθυλ, 5-(ετερο-)αρυλ υποκατεστημενα 1-η-πυρρολιου παραγωγα ως αναστολεις εκκρισης οξεος | |
| CY1113099T1 (el) | Παραγωγα (θειο)καρβαμοϋλ-κυκλοεξανιου ως ανταγωνιστες των υποδοχεων d3/d2 | |
| EA200971061A1 (ru) | Пиримидоновые соединения гетероариламидов | |
| MA28550B1 (fr) | Composes et procedes permettant de traiter la dyslipidemie | |
| UA83243C2 (ru) | Соединения, которые ингибируют натриезависимый переносчик глюкозы | |
| ATE556058T1 (de) | 1-(2h)-isochinolonderivat | |
| MY142018A (en) | Thiophene derivatives as chk 1 inihibitors | |
| NO20084701L (no) | Ny heterocyklisk forbindelse eller salt eller intermediat derav | |
| ATE478044T1 (de) | Biphenylderivate und ihre verwendung bei der behandlung von hepatitis c | |
| MY141255A (en) | Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs | |
| MX2016006685A (es) | Compuestos heterociclicos de n-acilimino. | |
| WO2009095792A3 (en) | Substituted heteroarylamide diazepinopyrimidone derivatives | |
| TW200602319A (en) | Indole derivative and use thereof | |
| MX2010008361A (es) | Derivados de arilamida oxazepinopirimidona sustituidos. | |
| MX2010008360A (es) | Derivados de oxazepinopirimidona heteroarilamida sustituidos. | |
| MY183326A (en) | New dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them | |
| EA200971060A1 (ru) | Гетероариламидные пиримидоновые производные | |
| ATE503746T1 (de) | Neue imidazolidinderivate | |
| BRPI0619894B8 (pt) | composto de amina e composição farmacêutica | |
| MX2007008308A (es) | Derivados de n-(heteroaril)-1h-indol-2-carboxamidas y su utilizacion como ligandos del receptor vaniloide trpv1-. |